Application of benzopyrimidine thioether compound as STING protein small-molecule inhibitor

By developing benzopyrimidine sulfide compounds as STING protein inhibitors, the problem of low potency of existing STING inhibitors has been solved, effective inhibition of STING signaling pathways has been achieved, and new treatments for chronic inflammatory and autoimmune diseases have been provided. drug applications.

CN119060061AActive Publication Date: 2024-12-03ZHEJIANG NORMAL UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411171823.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-03
Estimated Expiration
2044-08-26

AI Technical Summary

Technical Problem

The existing STING inhibitors have low potency and poor drug-like properties. They have not yet entered the clinical research stage, making it difficult to effectively treat chronic inflammatory and autoimmune diseases.

Method used

A benzopyrimidine thioether compound is developed as a small molecule inhibitor of STING protein, which significantly inhibits the activation of STING signaling pathway through specific structures and preparation routes, and is used to treat or prevent STING-mediated diseases.

Benefits of technology

The compound shows high STING protein inhibitory activity, with potential potential for the treatment of chronic inflammatory and autoimmune diseases, and provides a new pathway for drug application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060061A_ABST
    Figure CN119060061A_ABST
Patent Text Reader

Abstract

The invention discloses application of benzopyrimidine thioether compounds as STING protein small-molecule inhibitors, and relates to the technical field of inhibitors. It is found that the compound has a good effect in inhibition of STING signal channel activation, has high STING protein inhibition activity and can be applied to preparation of STING protein small-molecule inhibitors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of inhibitors, and in particular to the application of a class of benzopyrimidine thioether compounds as small molecule inhibitors of STING protein. Background Art

[0002] The cGAS-STING signaling pathway is an important component of the innate immune system. It can activate a strong immune response by nonspecifically recognizing DNA, thereby inducing the expression of IFN-β and other proinflammatory cytokines to resist the invasion of pathogens and inhibit tumor growth. The cGAS-STING signaling pathway can detect exogenous DNA in many organisms. This signaling pathway also combines DNA sensors with innate immune defense responses and plays an important role in host immune protection. Current studies have shown that the cGAS-STING signaling pathway involves the expression of IFN-β and is associated with the uptake of tumor-derived DNA by dendritic cells (DCs). In addition, activation of the STING pathway in tumor cells can induce the secretion of chemokines CCL5 (CC motif chemokine ligand 5) and CXCL10 (CX-Cmotif chemokine ligand 10), thereby promoting the recruitment and activation of NK cells and T cells in tumors.

[0003] Transient inflammatory signals are key to the body's defense against pathogen invasion, but persistent chronic inflammatory signals can lead to the induction of STING-related autoimmune and inflammatory diseases. For these diseases, STING small molecule inhibitors may become a potential treatment. Compared with the use of mature STING agonists as anti-tumor immunotherapy, research on STING inhibitors is still in its early stages. So far, reported STING inhibitors have shown limitations, including low efficacy or poor drug-like properties. And no STING small molecule inhibitors have entered the clinical research stage. Patients with chronic inflammatory and autoimmune diseases usually need to take medication for a long time, so the safety and potential side effects of STING inhibitors are crucial. Therefore, the development of a new skeleton with high efficacy, drug-like properties and less toxic side effects of STING small molecule inhibitors is of great significance for promoting the treatment of autoimmune and inflammatory diseases. Summary of the invention

[0004] The purpose of the present invention is to provide a benzopyrimidine thioether compound as a small molecule inhibitor of STING protein to solve the problems existing in the above-mentioned prior art.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] The present invention provides an application of a benzopyrimidine thioether compound in the preparation of a drug for inhibiting activation of a STING signaling pathway, wherein the compound has a structure shown in Formula I, Formula II or Formula III:

[0007]

[0008] Wherein, R1 is selected from any one of the following:

[0009]

[0010] L1 is selected from any of the following: H, -CH3, -CH2CH3;

[0011] R2 is selected from any of the following:

[0012]

[0013] R3 is selected from any of the following:

[0014]

[0015] The present invention also provides a use of a benzopyrimidine thioether compound in the preparation of a drug for treating or preventing a STING-mediated disease, wherein the compound has a structure shown in Formula I, Formula II or Formula III:

[0016]

[0017] Wherein, R1 is selected from any one of the following:

[0018]

[0019] L1 is selected from any of the following: H, -CH3, -CH2CH3;

[0020] R2 is selected from any of the following:

[0021]

[0022] R3 is selected from any of the following:

[0023]

[0024] Furthermore, the disease is an autoimmune disease or an inflammatory disease.

[0025] Furthermore, the disease includes STING-associated vasculopathy, Parkinson's disease, systemic lupus erythematosus or non-alcoholic fatty liver disease.

[0026] The present invention also provides a pharmaceutical composition for preventing or treating STING-mediated diseases, comprising a benzopyrimidine thioether compound having a structure represented by Formula I, Formula II or Formula III as an active ingredient:

[0027]

[0028] Wherein, R1 is selected from any one of the following:

[0029]

[0030] L1 is selected from any of the following: H, -CH3, -CH2CH3;

[0031] R2 is selected from any of the following:

[0032]

[0033] R3 is selected from any of the following:

[0034]

[0035] The preparation route of the compound of formula I is as follows:

[0036]

[0037]

[0038] The preparation route of the compound of formula II is as follows:

[0039] The preparation route of the compound of formula III is as follows:

[0040]

[0041] The present invention discloses the following technical effects:

[0042] The present invention provides a new application of a compound as a small molecule inhibitor of STING protein. The compound has a good effect in inhibiting the activation of STING signaling pathway, has a high STING protein inhibitory activity, and can be used in the preparation of small molecule inhibitors of STING protein. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0044] Figure 1 The inhibitory activity of compounds A1-A43 prepared in the examples of the present invention on STING protein;

[0045] Figure 2 The inhibitory activity of compounds D1-D12 prepared in the examples of the present invention on STING protein;

[0046] Figure 3 The inhibitory activity of compounds AB1-AB4 prepared in the examples of the present invention on STING protein. DETAILED DESCRIPTION

[0047] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0048] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0049] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0050] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0051] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0052] Example 1. Preparation of Compound A1. The specific steps of the preparation process are as follows:

[0053] Step I: First, weigh 0.8 g (20 mmol, 1 eq) of sodium hydroxide into a 100 mL eggplant-shaped bottle, dissolve it in 15 mL of water, then add 2.72 g (20 mmol, 1 eq) of benzoyl hydrazide (1) and 2.78 g (10 mmol, 0.5 eq) of S-methylisothiourea sulfate (2) to the system, then add 20 mL of water, stir at room temperature for 72 h, and then heat at 50 ° C for 3 h. After cooling, filter and wash with ice water, and a purple solid 3 can be obtained without further treatment; there is no need to calculate the yield in this step, and the next step reaction can be carried out directly.

[0054] Step II: The purple solid 3 obtained in the previous step was transferred to a 100 mL eggplant-shaped bottle, 30 mL of water was added as solvent, and the reaction was refluxed at 100°C for 2 h (the solution in the reaction system became clear and transparent). After cooling, needle-shaped white crystals were precipitated, which were filtered and washed with ice water, and dried to obtain crystals 4 (2.3 g, yield 72%).

[0055] Step III: Weigh 0.64 g (4 mmol, 1 eq) of amino-5-phenyl-1,2,4-triazole (4) into a reaction flask, add 1.04 g (8 mmol, 2 eq) of ethyl acetoacetate (5) into the system, then add 15 mL of acetic acid solvent, and reflux at 120°C for 6 h. During the reaction, it can be observed that the solution changes from clear to white solid precipitated. After the reaction is completed, cool, filter and wash with ethyl acetate (EA), and obtain white solid 6 (0.5 g, yield 55%) without further treatment.

[0056] Step IV: Take 0.5 g (2.2 mmol, 1 eq) of the white solid 6 obtained in the previous step into the reaction flask, add 1.5 mL of phosphorus oxychloride to the reaction flask, phosphorus oxychloride is used as both an oxidant and a reaction solvent, reflux at 100 ° C for 2 hours, and the reaction is completed by TLC detection. The solution in the reaction system turns brown-black, cools, and then slowly drops 4M sodium hydroxide solution in an ice-water bath to adjust the pH to about 10, and the pH test paper is used to detect the end of the dropwise addition time. A large amount of solid precipitates in the reaction system, which is first filtered, and the filter residue and filtrate are collected. The filtrate is extracted with water and dichloromethane (DCM), separated, and the organic phase is dried with anhydrous sodium sulfate and evaporated under reduced pressure for treatment. The filter residue is evaporated with anhydrous methanol under reduced pressure and mixed with the sample, and separated and purified by column chromatography (PE / EA=5:1) together with the filtrate to be treated to obtain a white solid 7 (0.21 g, yield 39%).

[0057] Step VIII: Weigh 0.5 g (4 mmol, 1 eq) of 2-aminobenzenethiol (8) into a dry Schlenk bottle, replace nitrogen with vacuum three times, add 15 mL of dry tetrahydrofuran (THF), inject 1.01 g (10 mmol, 2.5 eq) of triethylamine into the system with a syringe under an ice-water bath, and then slowly inject 1.36 g (8 mmol, 2 eq) of benzoyl chloride (9e) into the system with a syringe. Violent reaction can be seen in the system, and white solid is generated. Stir the reaction at room temperature for 6 h, and the reaction is completed by TLC detection. Add a large amount of water to the reaction system, extract with ethyl acetate (EA), separate the liquids, dry the organic phase with anhydrous sodium sulfate and evaporate under reduced pressure, and the residue is separated and purified by column chromatography-mass spectrometry (PE / EA=6:1) to obtain compound 10e (1.13 g, yield 72%).

[0058] Step IX: Weigh 1.1 g (2.8 mmol, 1 eq) of compound 10 into a reaction bottle, weigh 0.63 g (11.2 mmol, 4 eq) of potassium hydroxide into the system, and add 30 mL of anhydrous methanol (MeOH) as the reaction solvent. Stir the reaction at room temperature for 12 h. The reaction is completed by TLC. Slowly add hydrochloric acid solution to the reaction system to adjust the pH to neutral, detect with pH test paper, extract with water and dichloromethane (DCM), separate the liquids, dry the organic phase with anhydrous sodium sulfate, and evaporate under reduced pressure. The residue is separated and purified by column chromatography-mass spectrometry (PE / EA=7:1) to obtain a white solid 11e (0.49 g, yield 68%).

[0059] Step X: First, weigh 0.73 g (0.3 mmol, 1 eq) of compound 11e into a reaction bottle, then add 0.1 g (0.75 mmol, 2.5 eq) of potassium carbonate into the system, then add 15 mL of acetone solvent, and stir at 25°C for 30 min. Then, add 0.93 g (0.36 mmol, 1.2 eq) of compound 7 into the system, react at 25°C for 15 h, and the reaction is completed by TLC detection. After the reaction is completed, 0.1 M HCl solution is first added to the system to quench the reaction, then extracted with water and dichloromethane (DCM), separated, the organic phase is dried over anhydrous sodium sulfate and evaporated under reduced pressure, and the residue is separated and purified by column chromatography mass spectrometry (PE / EA=3:1) to obtain 15 mg of a white solid final product A1 with a yield of 7.5%.

[0060] 1H NMR (400MHz, DMSO-d6) δ10.81(s,1H),9.18(d,J=7.2Hz,1H),8.70-8.65(m,1H),8.15-8.11(m,2H),8.04(dd,J=7.8,1.9Hz,1H),7.78(dd,J=7.7, 1.6Hz,1H),7.69(ddd,J=8.7,7.4,1.6Hz,1H),7.53-7.49(m,4H),7.33(t d,J=7.5,1.4Hz,1H),7.17-7.13(m,2H),7.11-7.07(m,1H),3.86(s,3H).

[0061] Example 2. Preparation of compound A2. The preparation steps are different from those of A1 in that in step VIII, 4-methylbenzoyl chloride is used as a raw material to prepare the 10a derivative, and the corresponding 11a derivative is reacted with compound 18 to obtain a white solid A2 with a yield of 5.5%.

[0062] 1 H NMR (600MHz, DMSO-d6) δ10.13(s,1H),9.12(d,J=7.2Hz,1H),8.16-8.13(m,2H),7.80-7.78(m,3H),7.76(d,J=7.9Hz,1H), 7.65(s,1H),7.52(dd,J=5.3,2.0Hz,3H),7.45(d,J=7.5Hz,1H),7.28(d,J=7.9Hz,2H),6.97(d,J=7.2Hz,1H),2.33(s,3H).

[0063] Example 3. Preparation of compound A3. The preparation steps are different from those of A1 in that in step VIII, 2-methylbenzoyl chloride is used as a raw material to prepare the 10a derivative, and the corresponding 11a derivative is reacted with compound 7 to obtain a white solid A3 with a yield of 6.5%.

[0064] 1 H NMR (400MHz, DMSO-d6) δ10.29(s,1H),8.22(dd,J=6.7,2.9Hz,2H),7.89(dd,J=7.8,1.4Hz,1H),7.83(d,J=8.0Hz,1H),7.76(t,J=7.7Hz, 1H),7.56(dd,J=5.2,1.9Hz,3H),7.52(t,J=7.7Hz,1H),7.30(t,J=7.1Hz,2H),7.22-7.13(m,2H),6.20(s,1H),2.43(s,3H),2.22(s,3H).

[0065] Example 4. Preparation of compound A4. The preparation steps are different from those of A1 in that in step VIII, 4-methylbenzoyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is then reacted with compound 7 to obtain white solid A4 with a yield of 6.8%.

[0066] 1 H NMR (400MHz, DMSO-d6) δ10.30(s,1H),8.22(dd,J=6.7,2.9Hz,2H),7.90(dd,J=7.8,1.4Hz,1H),7.83(d,J=8.0Hz,1H),7.77(d,J=7.6Hz, 1H),7.57(dd,J=5.2,1.9Hz,3H),7.53(d,J=7.9Hz,1H),7.31(t,J=7.1Hz,2H),7.23-7.14(m,2H),6.21(s,1H),2.44(s,3H),2.23(s,3H).

[0067] Example 5. Preparation of compound A5. The preparation steps are different from those of A1 in that in step VIII, 4-chlorobenzoyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is then reacted with compound 7 to obtain white solid A5 with a yield of 7.8%.

[0068] 1 H NMR(400MHz,Chloroform-d)δ8.92(s,1H),8.48(dd,J=8.3,1.3Hz,1H),7.71-7.65(m,2H),7.57 -7.50(m,1H),7.47-7.39(m,3H),7.29(ddd,J=8.7,7.4,1.6Hz,1H),6.93(td,J=7.6,1.4Hz,1H).

[0069] Example 6. Preparation of compound A6. The preparation steps are different from those of A1 in that in step VIII, 3-methoxybenzoyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is then reacted with compound 7 to obtain white solid A6 with a yield of 6.5%.

[0070] 1H NMR (600MHz, DMSO-d6) δ10.38(s,1H),8.21-8.18(m,2H),7.91(dd,J=7.7,1.4Hz,1H),7.79-7.75(m,2H),7.57 -7.51(m,4H),7.44-7.41(m,1H),7.38-7.34(m,2H),7.11-7.09(m,1H),6.24(s,1H),3.72(s,3H),2.43(s,3H).

[0071] Example 7. Preparation of Compound A7. The preparation steps are different from those of A1 in that in step VIII, benzoyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is then reacted with compound 7 to obtain white solid A7 with a yield of 6.6%.

[0072] 1 H NMR(600MHz, DMSO-d6)δ10.49(s,1H),8.22(dt,J=6.6,2.7Hz,2H),7.91-7.86(m,2H),7.78(t,J=7.7 Hz,1H),7.58-7.51(m,4H),7.44-7.39(m,3H),7.34(td,J=7.2,1.7Hz,1H),6.15(s,1H),2.42(s,3H).

[0073] Example 8. Preparation of compound A8. The preparation steps are different from those of A1 in that: in step VIII, 3-fluorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 7 to obtain a white solid A8 with a yield of 6.9%.

[0074] 1 H NMR (400MHz, DMSO-d6) δ10.49(s,1H),8.22-8.18(m,2H),7.91(dd,J=7.6,1.2Hz,1H),7.78-7.75(m,2H),7.71(dt,J=7.7,1 .3Hz,1H),7.64(dt,J=9.9,2.1Hz,1H),7.58-7.54(m,4H),7.53-7.48(m,1H),7.43-7.37(m,1H),6.24(s,1H),2.43(s,3H).

[0075] Example 9. Preparation of compound A9. The preparation steps are different from those of A1 in that in step VIII, 2-chlorobenzoyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is then reacted with compound 7 to obtain white solid A9 with a yield of 7.2%.

[0076] 1 H NMR(600MHz, DMSO-d6)δ10.50(s,1H),8.23(dt,J=6.6,2.7Hz,2H),7.92-7.87(m,2H),7.79(t,J=7.7 Hz,1H),7.59-7.53(m,4H),7.45-7.40(m,3H),7.35(td,J=7.2,1.7Hz,1H),6.16(s,1H),2.43(s,3H).

[0077] Example 10. Preparation of compound A10. The preparation steps are different from those of A1 in that in step VIII, 2-fluorobenzoyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is reacted with compound 7 to obtain white solid A10 with a yield of 7.1%.

[0078] 1 H NMR (400MHz, DMSO-d6) δ10.29(d,J=2.4Hz,1H),8.22(dd,J=6.0,2.5Hz,2H),7.96(d,J=8.1Hz,1H),7.89(d,J=7.8Hz,1H),7.76(t,J =7.7Hz,1H),7.61(t,J=7.4Hz,1H),7.56(dd,J=4.1,2.6Hz,3H),7.50(t,J=7.8Hz,2H),7.28-7.19(m,2H),6.20(s,1H),2.42(s,3H).

[0079] Example 11. Preparation of compound A11. The preparation steps are different from those of A1 in that in step VIII, 4-fluorobenzoyl chloride is used as a raw material to prepare derivative 10a, which is then reacted with compound 7 to obtain white solid A11 with a yield of 6.9%.

[0080] 1 H NMR (400MHz, DMSO-d6) δ10.42 (s, 1H), 8.21-8.16 (m, 2H), 7.98-7.87 (m, 3H), 7.75 (d, J = 6.0Hz, 2H), 7.54 (t, J = 3.4Hz, 4H), 7.29 (t, J = 8.6Hz, 2H), 6.23 (d, J = 1.3Hz, 1H), 2.43 (d, J = 1.3Hz, 3H).

[0081] Example 12. Preparation of compound A12. The preparation steps are different from those of A1 in that in step VIII, 3-chlorobenzoyl chloride is used as a raw material to prepare the 10a derivative, which is then reacted with compound 7 to obtain a white solid A12 with a yield of 6.3%.

[0082] 1 H NMR (400MHz, DMSO-d6) δ10.52(s,1H),8.20(dd,J=6.6,3.0Hz,2H),7.91(d,J=7.8Hz,1H),7.86-7.78(m,2H),7.7 6(d,J=4.4Hz,2H),7.61(d,J=7.8Hz,1H),7.55(q,J=4.3Hz,4H),7.49(t,J=7.9Hz,1H),6.24(s,1H),2.43(s,3H).

[0083] Example 13. Preparation of compound A13. The preparation steps are different from those of A1 in that in step VIII, 4-bromobenzoyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is reacted with compound 7 to obtain white solid A13 with a yield of 6.5%.

[0084] 1 H NMR(400MHz,DMSO-d6)δ10.49(s,1H),8.22-8.16(m,2H),7.92-7.87(m,1H),7.83-7.78(m ,2H),7.77-7.73(m,2H),7.70-7.64(m,2H),7.58-7.45(m,5H),6.22(s,1H),2.42(s,3H).

[0085] Example 14. Preparation of compound A14. The preparation steps are different from those of A1 in that in step VIII, 4-methoxybenzoyl chloride is used as a raw material to prepare the 10a derivative, which is then reacted with compound 7 to obtain a white solid A14 with a yield of 7.5%.

[0086] 1 H NMR (400MHz, DMSO-d6) δ10.25(s,1H),8.19(dd,J=6.6,2.9Hz,2H),7.87(dd,J=10.0,7.7Hz,3H),7.78-7.70(m,2 H),7.55(dd,J=5.1,1.8Hz,3H),7.50(d,J=1.9Hz,1H),7.00-6.94(m,2H),6.22(s,1H),3.76(s,3H),2.42(s,3H).

[0087] Example 15. Preparation of compound A15. The preparation steps are different from those of A1 in that in step VIII, 2-bromobenzoyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is then reacted with compound 7 to obtain white solid A15 with a yield of 7.1%.

[0088] 1 H NMR(400MHz,DMSO-d6)δ10.50(s,1H),8.26-8.21(m,2H),7.93-7.84(m,2H),7.79(s, 1H),7.57(ddt,J=10.1,7.6,4.5Hz,5H),7.41-7.29(m,3H),6.16(s,1H),2.43(s,3H).

[0089] Example 16. Preparation of compound A16. The preparation steps are different from those of A1 in that in step VIII, 3-bromobenzoyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is then reacted with compound 7 to obtain white solid A16 with a yield of 7.3%.

[0090] 1 H NMR (400MHz, DMSO-d6) δ10.25(s,1H),8.20(dd,J=6.6,2.9Hz,2H),7.87(dd,J=10.0,7.7Hz,3H),7.79-7.71(m, 2H),7.58-7.53(m,3H),7.50(td,J=7.4,1.9Hz,1H),7.01-6.95(m,2H),6.23(s,1H),3.77(s,3H),2.43(s,3H).

[0091] Example 17. Preparation of compound A17. The preparation steps are different from those of A1 in that in step VIII, furanyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is reacted with compound 7 to obtain white solid A17 with a yield of 7.4%.

[0092] 1 H NMR (400MHz, DMSO-d6) δ10.26(s,1H),8.21(dd,J=5.8,2.7Hz,2H),7.87(d,J=8.1Hz,2H),7.81(d,J=8.0Hz,1H),7.73(t,J=7.7Hz,1H),7.55 (dd,J=4.6,2.5Hz,3H),7.50(t,J=7.6Hz,1H),7.28-7.24(m,1H),6.64(dt,J=3.4,1.6Hz,1H),6.21(d,J=1.5Hz,1H),2.42(d,J=1.5Hz,3H).

[0093] Example 18. Preparation of compound A18. The preparation steps are different from those of A1 in that in step VIII, the 10a derivative is prepared using thiophenecarbonyl chloride as a raw material, and the 11a derivative is then reacted with compound 7 to obtain white solid A18 with a yield of 7.8%.

[0094] 1 H NMR (400MHz, DMSO-d6) δ10.40(s,1H),8.22-8.18(m,2H),7.91-7.87(m,1H),7.85(dd,J=3.9,1.2Hz,1H),7.82(dd ,J=5.0,1.1Hz,1H),7.76-7.72(m,2H),7.56-7.50(m,4H),7.12(dd,J=5.0,3.8Hz,1H),6.22(s,1H),2.42(s,3H).

[0095] Example 19. Preparation of compound A19. The preparation steps are different from those of A1 in that in step VIII, 4-trifluoromethylbenzoyl chloride is used as a raw material to prepare derivative 10a, and derivative 11a is then reacted with compound 7 to obtain white solid A19 with a yield of 7.5%.

[0096] 1 H NMR (600MHz, DMSO-d6) δ10.64(s,1H),8.19-8.16(m,2H),8.04(d,J=8.2Hz,2H),7.91(dd,J=7.7,1 .4Hz,1H),7.83(d,J=8.2Hz,2H),7.79-7.74(m,2H),7.56-7.52(m,4H),6.23(s,1H),2.43(s,3H).

[0097] Example 20. Preparation of Compound A20. The preparation steps are different from those of A1 in that in step III, amino-5-phenyl-1,2,4-triazole (4) reacts with ethyl propionyl acetate (12) to obtain compound 13, and the subsequent reaction steps are the same as those of A1. In step VIII, 4-methylbenzoyl chloride is used as a raw material to obtain the 10a derivative, which is then reacted with compound 14 to obtain white solid A20 with a yield of 7.4%.

[0098] 1H NMR (400MHz, DMSO-d6) δ10.28(s,1H),8.23-8.17(m,2H),7.89(d,J=7.8Hz,1H),7.76(dd,J=13.6,7.8Hz,4H),7.55(t,J=3.5Hz,3H ),7.49(d,J=8.0Hz,1H),7.23(d,J=7.8Hz,2H),6.22(d,J=1.4Hz,1H),2.72-2.66(m,2H),2.30(s,3H),1.13(dd,J=8.1,6.8Hz,3H).

[0099] Example 21. Preparation of compound A21. The difference from the preparation of A20 is that in step VIII, 2-methoxybenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A21 with a yield of 6.7%.

[0100] 1 H NMR (400MHz, DMSO-d6) δ10.71 (s, 1H), 8.58 (d, J = 8.3Hz, 1H), 8.28-8.24 (m, 2H ),7.98(d,J=7.8Hz,1H),7.89(d,J=7.7Hz,1H),7.77(t,J=7.9Hz,1H),7.61-7. 57(m,3H),7.48(t,J=7.9Hz,1H),7.41(t,J=7.6Hz,1H),7.07(dd,J=13.1,7.9H z,2H),6.18(s,1H),3.64(s,3H),2.67(d,J=7.5Hz,2H),1.06(t,J=7.5Hz,3H).

[0101] Example 22. Preparation of compound A22. The difference from the preparation of A20 is that in step VIII, 4-bromobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A22 with a yield of 6.5%.

[0102] 1 H NMR(400MHz, DMSO-d6)δ10.47(s,1H),8.19(dd,J=6.6,3.0Hz,2H),7.92-7.88(m,1H),7.81-7.74(m ,4H),7.68-7.64(m,2H),7.57-7.52(m,4H),6.22(s,1H),2.72-2.66(m,2H),1.14(t,J=7.5Hz,3H).

[0103] Example 23. Preparation of compound A23. The difference from the preparation of A20 is that in step VIII, 4-fluorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A23 with a yield of 6.9%.

[0104] 1 H NMR(400MHz,DMSO-d6)δ10.44(s,1H),8.22-8.17(m,2H),7.96-7.88(m,3H),7.78-7.72(m,2H), 7.58-7.51(m,4H),7.29(t,J=8.9Hz,2H),6.22(s,1H),2.71-2.66(m,2H),1.14(t,J=7.5Hz,3H).

[0105] Example 24. Preparation of compound A24. The difference from the preparation of A20 is that in step VIII, 4-methoxybenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A24 with a yield of 7.9%.

[0106] 1 H NMR (400MHz, DMSO-d6) δ10.22(s,1H),8.22-8.17(m,2H),7.90-7.82(m,3H),7.79-7.68(m,2H),7.55(dd,J=5.0,2.0Hz,3H ),7.49(td,J=7.4,1.7Hz,1H),6.99-6.94(m,2H),6.21(s,1H),3.76(s,3H),2.68(d,J=7.5Hz,2H),1.13(t,J=7.5Hz,3H).

[0107] Example 25. Preparation of compound A25. The difference from the preparation of A20 is that in step VIII, 2-fluorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A25 with a yield of 8.1%.

[0108] 1H NMR (400MHz, DMSO-d6) δ10.31(d,J=2.5Hz,1H),8.26-8.21(m,2H),7.98(d,J=7.9Hz,1H),7.91(dd,J=7.8,1.5Hz,1H),7.77(td,J=7.8 ,1.6Hz,1H),7.63-7.56(m,4H),7.51(tt,J=7.9,2.4Hz,2H),7.28-7.19(m,2H),6.21(s,1H),2.73-2.67(m,2H),1.13(t,J=7.5Hz,3H).

[0109] Example 26. Preparation of compound A26. The difference from the preparation of A20 is that in step VIII, 2-bromobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A26 with a yield of 8.3%.

[0110] 1 H NMR (400MHz, DMSO-d6) δ10.49(s,1H),8.25-8.21(m,2H),7.92-7.86(m,2H),7.79(t,J=7.7Hz,1 H),7.60-7.51(m,5H),7.39-7.30(m,3H),6.14(s,1H),2.72-2.66(m,2H),1.14(t,J=7.5Hz,3H).

[0111] Example 27. Preparation of compound A27. The difference from the preparation of A20 is that in step VIII, 4-trifluoromethylbenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A27 with a yield of 8.0%.

[0112] 1 H NMR (400MHz, DMSO-d6) δ10.65(s,1H),8.22-8.17(m,2H),8.04(d,J=8.1Hz,2H),7.92(dd,J=7.7,1.3Hz,1H),7.84(d, J=8.2Hz,2H),7.80-7.74(m,2H),7.56(dd,J=7.2,2.8Hz,4H),6.24(s,1H),2.72-2.66(m,2H),1.15(t,J=7.5Hz,3H).

[0113] Example 28. Preparation of compound A28. The difference from the preparation of A20 is that in step VIII, 2-methylbenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A28 with a yield of 7.0%.

[0114] 1 H NMR(600MHz,DMSO-d6)δ10.32(s,1H),8.24-8.21(m,2H),7.90(dd,J=7.8,1.5Hz, 1H),7.83(dd,J=8.1,1.4Hz,1H),7.77(td,J=7.8,1.5Hz,1H),7.59-7.55(m,3H),7 .52(td,J=7.6,1.5Hz,1H),7.31-7.27(m,2H),7.20(d,J=7.5Hz,1H),7.16(t,J=7 .5Hz,1H),6.19(s,1H),2.70(q,J=7.5Hz,2H),2.19(s,3H),1.14(t,J=7.5Hz,3H).

[0115] Example 29. Preparation of compound A29. The difference from the preparation of A20 is that in step VIII, 3-methylbenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A29 with a yield of 7.6%.

[0116] 1 H NMR (600MHz, DMSO-d6) δ10.33(s,1H),8.22-8.18(m,2H),7.90(dd,J=7.9,1.5Hz,1H),7.78-7.73(m,2H),7.61(dd,J=5.3,3.7Hz,1H),7. 57-7.54(m,4H),7.51(td,J=7.4,1.8Hz,1H),7.34-7.29(m,2H),6.22(s,1H),2.68(q,J=7.5Hz,2H),2.25(s,3H),1.13(t,J=7.5Hz,3H).

[0117] Example 30. Preparation of compound A30. The difference from the preparation of A20 is that in step VIII, 3-bromobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A30 with a yield of 7.2%.

[0118] 1H NMR (600MHz, DMSO-d6) δ10.53(s,1H),8.21-8.17(m,2H),7.95(t,J=1.9Hz,1H),7.91(dd,J=7.7,1.1Hz,1H),7.82(dt,J=7.8,1. 3Hz,1H),7.77-7.72(m,3H),7.57-7.51(m,4H),7.41(t,J=7.9Hz,1H),6.22(s,1H),2.68(d,J=7.6Hz,2H),1.13(t,J=7.5Hz,3H).

[0119] Example 31. Preparation of compound A31. The difference from the preparation of A20 is that in step VIII, 3-methoxybenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A31 with a yield of 6.8%.

[0120] 1 H NMR (400MHz, DMSO-d6) δ10.38(s,1H),8.19(dd,J=6.6,3.1Hz,2H),7.91(dd,J=7.7,1.3Hz,1H),7.80-7.72(m,2H),7.58-7.49(m,4H),7.41(dt, J=7.7,1.3Hz,1H),7.37-7.30(m,2H),7.09(ddd,J=8.1,2.7,1.1Hz,1H),6.22(s,1H),3.71(s,3H),2.69(d,J=7.5Hz,2H),1.14(t,J=7.5Hz,3H).

[0121] Example 32. Preparation of compound A32. The difference from the preparation of A20 is that in step VIII, 3-fluorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A32 with a yield of 6.4%.

[0122] 1H NMR (400MHz, DMSO-d6) δ10.37(s,1H),8.19(dd,J=6.6,3.1Hz,2H),7.90(dd,J=7.7,1.3Hz,1H),7.75(qd,J=8.1,1.8Hz,2H),7.58-7.49(m,4H),7.40 (dt,J=7.7,1.3Hz,1H),7.37-7.29(m,2H),7.08(ddd,J=8.1,2.7,1.1Hz,1 H), 6.22 (s, 1H), 3.70 (s, 3H), 2.68 (d, J = 7.5Hz, 2H), 1.13 (t, J = 7.5Hz, 3H).

[0123] Example 33. Preparation of compound A33. The difference from the preparation of A20 is that in step VIII, 4-chlorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A33 with a yield of 6.6%.

[0124] 1 H NMR (400MHz, DMSO-d6) δ10.49 (s, 1H), 8.21-8.17 (m, 2H), 7.90 (dd, J = 7.6, 1.3Hz, 1H), 7.88-7.85 (m, 2H), 7.77 -7.74(m,2H),7.57-7.53(m,5H),7.52(d,J=2.1Hz,1H),6.22(s,1H),2.70-2.66(m,2H),1.14(t,J=7.5Hz,3H).

[0125] Example 34. Preparation of compound A34. The difference from the preparation of A20 is that in step VIII, furanyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A34 with a yield of 8.6%.

[0126] 1 H NMR(600MHz,DMSO-d6)δ10.26(s,1H),8.23-8.20(m,2H),7.90-7.85(m,2H), 7.81(dd,J=8.2,1.4Hz,1H),7.74(dd,J=7.6,1.5Hz,1H),7.56(dd,J=5.3,2. 0Hz, 3H), 7.51 (dd, J=7.7, 1.4Hz, 1H), 7.25 (dd, J=3.6, 0.8Hz, 1H), 6.63 (dd, J=3.5,1.8Hz,1H),6.20(s,1H),2.69(q,J=7.5Hz,2H),1.13(t,J=7.5Hz,3H).

[0127] Example 35. Preparation of compound A35. The difference from the preparation of A20 is that in step VIII, the 10a derivative is prepared using thiophenecarbonyl chloride as the raw material, and the 11a derivative is then reacted with compound 14 to obtain white solid A35 with a yield of 8.8%.

[0128] 1 H NMR (600MHz, DMSO-d6) δ10.35(d,J=3.9Hz,1H),8.20-8.17(m,1H),8.09-8.06(m,1H),7.90-7.87(m,1H),7.74(dt,J=6.5,1.5Hz,2H),7.62(d d,J=7.0,2.0Hz,1H),7.58(d,J=4.1Hz,1H),7.55-7.50(m,2H),7.36-7.31(m,3H),6.21(d,J=14.7Hz,1H),2.41(d,J=6.1Hz,3H),2.38(s,2H).

[0129] Example 36. Preparation of compound A36. The difference from the preparation steps of A1 is that in step VIII, 2,6-difluorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 7 to obtain a white solid A36 with a yield of 9.4%.

[0130] 1 H NMR (400MHz, DMSO-d6) δ10.78 (s, 1H), 8.29-8.19 (m, 2H), 7.90 (td, J = 8.1, 1.4Hz, 2H), 7.84-7.7 5(m,1H),7.60-7.52(m,4H),7.51-7.43(m,1H),7.11(t,J=8.1Hz,2H),6.15(s,1H),2.41(s,3H).

[0131] Example 37. Preparation of compound A37. The difference from the preparation steps of A1 is that in step VIII, 3,5-difluorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 7 to obtain a white solid A37 with a yield of 9.1%.

[0132] 1H NMR (400MHz, DMSO-d6) δ10.55(s,1H),8.21-8.17(m,2H),7.93-7.89(m,1H),7.75(dd,J=6. 3,1.7Hz,2H),7.55(dp,J=7.8,2.7Hz,6H),7.48(d,J=2.4Hz,1H),6.23(s,1H),2.43(s,3H).

[0133] Example 38. Preparation of compound A38. The difference from the preparation steps of A1 is that in step VIII, 4,5-difluorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 7 to obtain a white solid A38 with a yield of 9.4%.

[0134] 1 H NMR (400MHz, Chloroform-d) δ10.79 (s, 1H), 8.77-8.67 (m, 2H), 8.58 (ddd, J = 23.4, 7.2, 1.7Hz, 2H), 8. 39(s,1H),8.20-8.09(m,2H),8.06(s,1H),8.02(s,1H),7.84-7.73(m,2H),5.63(s,2H),3.10(s,3H).

[0135] Example 39. Preparation of compound A39. The difference from the preparation steps of A1 is that in step VIII, 4,5-dichlorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 7 to obtain a white solid A39 with a yield of 9.2%.

[0136] 1 H NMR (600MHz, DMSO-d6) δ10.58(s,1H),8.20-8.17(m,2H),8.03(d,J=2.1Hz,1H),7.91(dd,J=7.6,1.3Hz,1 H),7.81(dd,J=8.4,2.1Hz,1H),7.76-7.73(m,3H),7.55(dd,J=5.2,1.9Hz,4H),6.23(s,1H),2.42(s,3H).

[0137] Example 40. Preparation of compound A40. The difference from the preparation steps of A1 is that in step VIII, 5,6-dichlorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 7 to obtain a white solid A40 with a yield of 8.2%.

[0138] 1H NMR (400MHz, DMSO-d6) δ10.57(s,1H),8.26-8.19(m,2H),7.90(dd,J=7.8,1.7Hz,2H),7.79(t,J=7.7 Hz,1H),7.68(dd,J=7.3,2.3Hz,1H),7.59-7.52(m,4H),7.41-7.35(m,2H),6.16(s,1H),2.43(s,3H).

[0139] Example 41. Preparation of compound A41. The preparation steps are different from those of A1 in that in step VIII, 3,5-dichlorobenzoyl chloride is used as a raw material to prepare the 10a derivative, which is then reacted with compound 7 to obtain a white solid A41 with a yield of 8.6%.

[0140] 1 H NMR (400MHz, DMSO-d6) δ10.60(s,1H),8.22-8.16(m,2H),7.94-7.89(m,1H),7.80(q,J=1.6 Hz,3H),7.75(dd,J=6.8,1.7Hz,2H),7.55(qd,J=4.3,2.7Hz,4H),6.23(s,1H),2.42(s,3H).

[0141] Example 42. Preparation of compound A42. The difference from the preparation of A20 is that in step VIII, 2,6-difluorobenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 14 to obtain a white solid A42 with a yield of 7.5%.

[0142] 1 H NMR (600MHz, DMSO-d6) δ10.79(s,1H),8.25-8.21(m,2H),7.90(ddd,J=13.3,7.9,1.5Hz,2H),7.79(td,J=7.8,1.6Hz,1H),7.59- 7.52(m,4H),7.47(ddd,J=8.6,6.7,1.9Hz,1H),7.10(t,J=8.1Hz,2H),6.14(s,1H),2.68(d,J=7.6Hz,2H),1.12(t,J=7.5Hz,3H).

[0143] Example 43. Preparation of compound A43. The difference from the preparation steps of A1 is that in step VIII, 4-p-ethoxybenzoyl chloride is used as the raw material to prepare the 10a derivative, and the 11a derivative is then reacted with compound 7 to obtain a white solid A43 with a yield of 8.4%.

[0144] 1 H NMR(600MHz,DMSO-d6)δ10.23(s,1H),8.22-8.16(m,2H),7.87(dd,J=7.8,1 .5Hz,1H),7.85-7.82(m,2H),7.77-7.75(m,1H),7.73(dd,J=7.2,1.5Hz,1H ),7.55(dd,J=5.1,2.0Hz,3H),7.50(dd,J=7.5,1.7Hz,1H),6.97-6.93(m,2 H), 6.22 (s, 1H), 4.03 (d, J = 7.0Hz, 2H), 2.42 (s, 3H), 1.30 (t, J = 7.0Hz, 3H).

[0145] Example 44. Preparation of compound D1. The synthetic route is the same as the preparation route of the compound of formula II. 19a is used as the raw material and a 4-step reaction is performed to obtain compound 23b, which is then reacted with 26 to obtain the final product D1 with a yield of 4.8%.

[0146] 1 H NMR(600MHz,DMSO-d6)δ10.24(s,1H),8.10-8.06(m,2H),7.88-7.83(m,3H),7.76-7.71(m,2H),7.49(d, J=1.7Hz,1H),7.36-7.33(m,2H),6.98-6.95(m,2H),6.20(s,1H),3.76(s,3H),2.41(s,3H),2.38(s,3H).

[0147] Example 45. Preparation of compound D2. The synthetic route is the same as the preparation route of the compound of formula II. 19b is used as the raw material to obtain compound 23b through 4 steps of reaction, and then reacted with 26 to obtain the final product D2 with a yield of 4.5%.

[0148] 1 H NMR(600MHz,DMSO-d6)δ10.24(s,1H),8.22-8.16(m,2H),7.88-7.83(m,3H),7.76-7.71(m,2H), 7.63-7.59(m,2H),7.51-7.47(m,1H),6.99-6.94(m,2H),6.23(s,1H),3.76(s,3H),2.42(s,3H).

[0149] Example 46. Preparation of compound AD3. The synthetic route is the same as the preparation route of the compound of formula II. 19c is used as the raw material to obtain compound 23c through 4 steps of reaction, and then reacted with 26 to obtain the final product D3 with a yield of 4.7%.

[0150] 1 H NMR(400MHz,DMSO-d6)δ10.22(s,1H),8.27-8.19(m,2H),7.89-7.82(m,3H),7.78-7.70(m,2H),7.49(dd d,J=7.9,7.0,1.9Hz,1H),7.41-7.34(m,2H),7.02-6.94(m,2H),6.23(s,1H),3.77(s,3H),2.42(s,3H).

[0151] Example 47. Preparation of compound D4. The synthetic route is the same as the preparation route of the compound of formula II. 19d is used as the raw material and a 4-step reaction is performed to obtain compound 23d, which is then reacted with 26 to obtain the final product D4 with a yield of 5.4%.

[0152] 1 H NMR(400MHz, DMSO-d6)δ10.23(s,1H),8.16(td,J=7.7,1.8Hz,1H),7.90-7.82(m,3H),7.78-7.69(m,2H),7.62-7.56(m ,1H),7.49(ddd,J=8.8,7.0,1.9Hz,1H),7.43-7.36(m,2H),7.00-6.94(m,2H),6.23(s,1H),3.77(s,3H),2.43(s,3H).

[0153] Example 48. Preparation of compound D5. The synthetic route is the same as the preparation route of the compound of formula II. 19e is used as the raw material and a 4-step reaction is performed to obtain compound 23e, which is then reacted with 26 to obtain the final product D5 with a yield of 5.9%.

[0154] 1 H NMR(400MHz, DMSO-d6)δ10.23(s,1H),8.04(dt,J=7.8,1.2Hz,1H),7.90-7.83(m,4H),7.78-7.70(m,2H),7.61(td,J=8.1,5 .9Hz,1H),7.50(ddd,J=7.8,6.9,2.0Hz,1H),7.43-7.37(m,1H),7.01-6.94(m,2H),6.26(s,1H),3.77(s,3H),2.43(s,3H).

[0155] Example 49. Preparation of compound D6. The synthetic route is the same as the preparation route of the compound of formula II. 19f is used as the raw material to obtain compound 23f through 4 steps of reaction, and then reacted with 26 to obtain the final product D6 with a yield of 4.9%.

[0156] 1 H NMR (600MHz, DMSO-d6) δ10.23(s,1H),8.15-8.09(m,2H),7.89-7.83(m,3H),7.78-7.70(m,2H),7.49(td,J= 7.5,1.6Hz,1H),7.11-7.07(m,2H),7.00-6.95(m,2H),6.18(s,1H),3.83(s,3H),3.77(s,3H),2.40(s,3H).

[0157] Example 50. Preparation of compound D7. The synthetic route is the same as the preparation route of the compound of formula II. 19g is used as the raw material and a 4-step reaction is performed to obtain compound 23g, which is then reacted with 26 to obtain the final product D7 with a yield of 4.5%.

[0158] 1 H NMR (600MHz, DMSO-d6) δ10.26(s,1H),7.88(dd,J=7.7,1.5Hz,1H),7.87-7.81(m,3H),7.77-7.71(m,2H),7.50(tdd,J=7.5,4.1,1.8Hz ,2H),7.19(dd,J=8.5,1.0Hz,1H),7.08(td,J=7.5,1.0Hz,1H),7.00-6.95(m,2H),6.20(s,1H),3.82(s,3H),3.77(s,3H),2.41(s,3H).

[0159] Example 51. Preparation of compound D8. The synthetic route is the same as the preparation route of the compound of formula II. 19h is used as the raw material and a 4-step reaction is performed to obtain compound 23h, which is then reacted with 26 to obtain the final product D8 with a yield of 4.5%.

[0160] 1H NMR (400MHz, DMSO-d6) δ10.22(s,1H),8.28(t,J=1.8Hz,1H),8.18(dt,J=7.8,1.2Hz,1H),7.89-7.82(m ,3H),7.78-7.70(m,3H),7.54-7.48(m,2H),7.00-6.94(m,2H),6.26(s,1H),3.77(s,3H),2.43(s,3H).

[0161] Example 52. Preparation of compound D9. The synthetic route is the same as the preparation route of the compound of formula II. 19i is used as the raw material to obtain compound 23i through 4 steps of reaction, and then reacts with 26 to obtain the final product D9 with a yield of 4.5%.

[0162] 1 H NMR (400MHz, DMSO-d6) δ10.22(s,1H),7.96(dd,J=7.5,2.0Hz,1H),7.88(dd,J=7.8,1.4Hz,1H),7.86-7.81(m,2H),7.78-7.71(m, 2H),7.64(dd,J=7.8,1.5Hz,1H),7.58-7.53(m,1H),7.53-7.47(m,2H),7.00-6.95(m,2H),6.28(s,1H),3.78(s,3H),2.44(s,3H).

[0163] Example 53. Preparation of compound D10. The synthetic route is the same as the preparation route of the compound of formula II. 19j is used as the raw material to obtain compound 23j through 4 steps of reaction, and then reacted with 26 to obtain the final product D10, with a yield of 5.1%.

[0164] 1 H NMR (400MHz, CDCl3) δ8.80(s,1H),8.72(dd,J=8.4,1.3Hz,1H),8.38(d,J=1.9Hz,1H),8.26(dt,J=7.0,1.7Hz,1H),7.75-7.72(m,2H ),7.71-7.68(m,2H),7.48-7.42(m,2H),7.31(td,J=7.6,1.4Hz,1H),6.86(d,J=8.9Hz,2H),6.17(s,1H),3.78(s,3H),2.51(s,3H).

[0165] Example 54. Preparation of compound D11. The synthetic route is the same as the preparation route of the compound of formula II. 19k is used as the raw material to obtain compound 23k through 4 steps of reaction, and then reacts with 26 to obtain the final product D11 with a yield of 5.3%.

[0166] 1 H NMR(400MHz, DMSO-d6)δ10.22(s,1H),7.93(dd,J=1.8,0.8Hz,1H),7.88-7.82(m,3H),7.78-7.70(m,2H),7.53-7.46(m, 1H),7.23(dd,J=3.4,0.8Hz,1H),7.02-6.94(m,2H),6.71(dd,J=3.4,1.8Hz,1H),6.21(s,1H),3.77(s,3H),2.41(s,3H).

[0167] Example 55. Preparation of compound D12. The synthetic route is the same as the preparation route of the compound of formula II. 191 is used as the raw material to obtain compound 231 through 4 steps of reaction, and then reacts with 26 to obtain the final product D12 with a yield of 6.2%.

[0168] 1 H NMR (600MHz, DMSO-d6) δ10.31(s,1H),8.09-8.06(m,2H),7.87(dd,J=7.8,1.5Hz,1H),7.77-7.71(m,4H),7.50(td,J=7 .5,1.7Hz,1H),7.35(dd,J=8.3,2.2Hz,2H),7.24(d,J=8.1Hz,2H),6.19(s,1H),2.41(s,3H),2.38(s,3H),2.30(s,3H).

[0169] Example 56. Preparation of Compound AB1. Synthesis route is the same as that of the compound of formula III, wherein the synthesis steps of compound 7 are the same as those of A1. The last step is the same as A1, 2-naphthalenethiol (29) reacts with compound 7 to obtain orange solid AB1, with a yield of 34%.

[0170] 1H NMR(600MHz,Chloroform-d)δ8.43-8.40(m,2H),8.30(d,J=1.8Hz,1H),8.04(d,J=8.6Hz,1H),8.00-7. 97(m,1H),7.95(dd,J=8.0,1.3Hz,1H),7.70-7.63(m,3H),7.53-7.49(m,3H),6.09(s,1H),2.45(s,3H).

[0171] Example 57. Preparation of Compound AB2. Synthesis route is the same as that of the compound of formula III, wherein the synthesis steps of compound 7 are the same as those of A1. The last step is the same as that of A1, where benzothiazole-2-thiol (30) reacts with compound 7 to obtain solid product AB2 with a yield of 38%.

[0172] 1 H NMR (400MHz, DMSO-d6) δ8.27-8.23(m,1H),8.21-8.15(m,3H),7.67-7.58(m,2H),7.58-7.53(m,3H),7.24(s,1H),2.57(s,3H).

[0173] Example 58. Preparation of compound AB3. The synthetic route is the same as that of the compound of formula III, wherein the synthetic steps of compound 7 are the same as those of A1. The last step is the same as that of A1, where 1-phenyl-5-mercaptotetrazole (31) reacts with compound 7 to obtain solid product AB3 with a yield of 31%.

[0174] 1 H NMR (400MHz, DMSO-d6) δ8.10 (ddd, J=6.1, 2.4, 1.5Hz, 2H), 7.83-7.77 (m, 2H), 7.62(tt,J=4.2,2.9Hz,3H),7.54(h,J=2.8Hz,3H),7.12(s,1H),2.55(s,3H).

[0175] Example 59. Preparation of compound AB4. The synthetic route is the same as the preparation route of the compound of formula III, wherein the synthetic steps of compound 7 are the same as A1, white solid AB4, with a yield of 21%.

[0176] 1 H NMR (600MHz, DMSO-d6) δ8.16-8.13(m,2H),8.11-8.08(m,2H),7.72-7.69(m,1H),7.68-7.64(m,2H),7.54-7.48(m,3H),7.38(s,1H),2.58(s,3H).

[0177] The compound structures are shown in Tables 1-3.

[0178] Table 1 Structure of compounds of formula I

[0179]

[0180]

[0181]

[0182] Table 2 Structure of compound of formula II

[0183]

[0184]

[0185] Table 3 Structure of compound of formula III

[0186]

[0187] Effect verification example

[0188] Luciferase reporter gene assay system. 190 μL of THP-1-luc cells in good condition were plated at 5×10 5 The density of cells / well was evenly spread in a 96-well plate, and THP-1-luc cells were treated differently: the group with c-di-GMP added was used as the activation control group (the final concentration of c-di-GMP was 10μg / mL); the group with c-di-GMP and test compounds added was used as the experimental group (the final concentration of c-di-GMP was 10μg / mL, and the final concentration of test compounds was 5μM); the group without c-di-GMP and test compounds added was used as the blank control group. Among them, each group contained an equal amount of DMSO (solvent), and the final concentration of DMSO in each group was 0.1vol.%. Finally, the cells were cultured at 37°C and 5% CO2 for 48h. Then 10μL of supernatant was taken out from each well and added to the opaque white plate of the 96-well plate for luciferase activity analysis. The program of the microplate reader is: 50μL injection per well, 4 seconds start time, 0.1 second reading time. The IC50 value was measured, and the concentration gradient of the compound was 20.0 μM, 10.0 μM, 5.0 μM, 2.5 μM, 1.25 μM, 0.625 μM, and 0.3125 μM. The inhibition rate was measured and the IC50 was calculated.

[0189] The inhibitory activity data of each compound on STING protein in THP1-Dual cells are shown in Table 4 and Figure 1-Figure 3 .

[0190] Table 4 IC50 of some compounds

[0191]

[0192]

[0193] Among the 59 compounds prepared in the examples of the present invention, A8, A9, A10, A11, A12, A14, A16, A24, A32, A34, and D1 have good inhibitory activity on the activation of STING protein (Table 4), among which A24 has the best activity.

[0194] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Use of a benzopyrimidine thioether compound in the preparation of a drug for inhibiting activation of the STING signaling pathway, It is characterized in that The compound has a structure shown in Formula I, Formula II or Formula III: Among them, R 1 Choose from any of the following: L 1 Select any one of the following: H, -CH 3 、-CH 2 CH 3 ; R 2 Choose from any of the following: R 3 Choose from any of the following:

2. Use of a benzopyrimidine thioether compound in the preparation of a drug for treating or preventing STING-mediated diseases, It is characterized in that The compound has a structure shown in Formula I, Formula II or Formula III: Among them, R 1 Choose from any of the following: L 1 Select any one of the following: H, -CH 3 、-CH 2 CH 3 ; R 2 Choose from any of the following: R 3 Choose from any of the following:

3. The use according to claim 2, It is characterized in that The disease is an autoimmune disease or an inflammatory disease.

4. The use according to claim 3, It is characterized in that The diseases include STING-associated vasculopathy, Parkinson's disease, systemic lupus erythematosus or non-alcoholic fatty liver disease.

5. A pharmaceutical composition for preventing or treating a STING-mediated disease, It is characterized in that A benzopyrimidine sulfide compound containing a structure represented by formula I, formula II or formula III as an active ingredient: Among them, R 1 Choose from any of the following: L 1 Select any one of the following: H, -CH 3 、-CH 2 CH 3 ; R 2 Choose from any of the following: R 3 Choose from any of the following:

Citation Information

Patent Citations

  • Casein kinase 1δ (CK1δ) inhibitors

    CN103298460B

  • Casein Kinase 1delta (ck 1delta) Inhibitors

    CN105920010A

  • Pyrimido-1, 2, 4-triazole compound and preparation method and application thereof

    CN108484612A

  • Application of BMX inhibitor in preparation of medicine for treating fundus neovascularization diseases

    CN118766923A

  • Inhibitors of mitotic kinesin

    WO2007011759A2